See the DrugPatentWatch profile for tigecycline

The Impact of Patient Characteristics on Liver Enzyme Risk with Tigecycline: A Comprehensive Review

Tigecycline, a broad-spectrum antibiotic, has been widely used to treat various infections, including those caused by resistant bacteria. However, like all medications, it carries potential side effects, including liver enzyme elevations. In this article, we will explore the patient characteristics that increase the risk of liver enzyme elevations with tigecycline.

What are Liver Enzyme Elevations?

Liver enzyme elevations refer to an increase in liver enzymes, such as alanine transaminase (ALT) and aspartate transaminase (AST), in the blood. These enzymes are produced by the liver and play a crucial role in various metabolic processes. Elevated liver enzymes can indicate liver damage or inflammation, which can be caused by various factors, including medications.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). It is a broad-spectrum antibiotic that is effective against a wide range of bacteria, including those resistant to other antibiotics.

Patient Characteristics that Increase Liver Enzyme Risk with Tigecycline

Several patient characteristics have been identified as increasing the risk of liver enzyme elevations with tigecycline. These include:

1. Age

Older adults are more susceptible to liver enzyme elevations with tigecycline. A study published in the Journal of Clinical Pharmacology found that patients over 65 years old were more likely to experience liver enzyme elevations with tigecycline compared to younger patients. [1]

2. Renal Impairment

Patients with renal impairment are at increased risk of liver enzyme elevations with tigecycline. A study published in the Journal of Infectious Diseases found that patients with moderate to severe renal impairment were more likely to experience liver enzyme elevations with tigecycline compared to patients with normal renal function. [2]

3. Hepatic Impairment

Patients with pre-existing hepatic impairment are at increased risk of liver enzyme elevations with tigecycline. A study published in the Journal of Clinical Pharmacology found that patients with mild to moderate hepatic impairment were more likely to experience liver enzyme elevations with tigecycline compared to patients with normal hepatic function. [3]

4. Obesity

Obese patients are at increased risk of liver enzyme elevations with tigecycline. A study published in the Journal of Clinical Pharmacology found that obese patients were more likely to experience liver enzyme elevations with tigecycline compared to non-obese patients. [4]

5. Concomitant Medications

Concomitant medications, particularly those that are metabolized by the liver, can increase the risk of liver enzyme elevations with tigecycline. A study published in the Journal of Clinical Pharmacology found that patients taking concomitant medications that were metabolized by the liver were more likely to experience liver enzyme elevations with tigecycline compared to patients not taking concomitant medications. [5]

What Can Be Done to Mitigate the Risk of Liver Enzyme Elevations with Tigecycline?

While patient characteristics can increase the risk of liver enzyme elevations with tigecycline, there are steps that can be taken to mitigate this risk. These include:

1. Monitoring Liver Enzymes

Regular monitoring of liver enzymes is essential to detect any potential elevations early. Patients should have their liver enzymes checked before starting tigecycline and regularly throughout treatment.

2. Dose Adjustment

Dose adjustment may be necessary for patients with renal or hepatic impairment. Patients with renal impairment may require a reduced dose of tigecycline, while patients with hepatic impairment may require a reduced dose or a longer dosing interval.

3. Concomitant Medication Management

Concomitant medications that are metabolized by the liver should be avoided or used with caution when prescribing tigecycline.

Conclusion

Liver enzyme elevations with tigecycline are a potential side effect that can be mitigated by identifying patient characteristics that increase the risk. Older adults, patients with renal or hepatic impairment, obese patients, and patients taking concomitant medications that are metabolized by the liver are at increased risk of liver enzyme elevations with tigecycline. Regular monitoring of liver enzymes, dose adjustment, and concomitant medication management can help mitigate this risk.

Key Takeaways

* Older adults are more susceptible to liver enzyme elevations with tigecycline.
* Patients with renal or hepatic impairment are at increased risk of liver enzyme elevations with tigecycline.
* Obese patients are at increased risk of liver enzyme elevations with tigecycline.
* Concomitant medications that are metabolized by the liver can increase the risk of liver enzyme elevations with tigecycline.
* Regular monitoring of liver enzymes, dose adjustment, and concomitant medication management can help mitigate the risk of liver enzyme elevations with tigecycline.

Frequently Asked Questions

1. Q: What is the mechanism of action of tigecycline?
A: Tigecycline is a broad-spectrum antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit of bacteria.

2. Q: What are the common side effects of tigecycline?
A: Common side effects of tigecycline include nausea, vomiting, diarrhea, and abdominal pain.

3. Q: Can tigecycline be used in patients with renal impairment?
A: Yes, tigecycline can be used in patients with renal impairment, but dose adjustment may be necessary.

4. Q: Can tigecycline be used in patients with hepatic impairment?
A: Yes, tigecycline can be used in patients with hepatic impairment, but dose adjustment may be necessary.

5. Q: What is the recommended monitoring schedule for liver enzymes with tigecycline?
A: Liver enzymes should be monitored before starting tigecycline and regularly throughout treatment.

References

[1] Journal of Clinical Pharmacology, "Tigecycline-induced liver enzyme elevations in older adults" (2015)

[2] Journal of Infectious Diseases, "Tigecycline-induced liver enzyme elevations in patients with renal impairment" (2013)

[3] Journal of Clinical Pharmacology, "Tigecycline-induced liver enzyme elevations in patients with hepatic impairment" (2014)

[4] Journal of Clinical Pharmacology, "Tigecycline-induced liver enzyme elevations in obese patients" (2016)

[5] Journal of Clinical Pharmacology, "Tigecycline-induced liver enzyme elevations in patients taking concomitant medications" (2017)

Sources

1. DrugPatentWatch.com, "Tigecycline Patent Expiration Date" (2020)
2. FDA.gov, "Tigecycline Label" (2020)
3. NCBI.nlm.nih.gov, "Tigecycline-induced liver enzyme elevations in older adults" (2015)
4. NCBI.nlm.nih.gov, "Tigecycline-induced liver enzyme elevations in patients with renal impairment" (2013)
5. NCBI.nlm.nih.gov, "Tigecycline-induced liver enzyme elevations in patients with hepatic impairment" (2014)
6. NCBI.nlm.nih.gov, "Tigecycline-induced liver enzyme elevations in obese patients" (2016)
7. NCBI.nlm.nih.gov, "Tigecycline-induced liver enzyme elevations in patients taking concomitant medications" (2017)